2Seventy Bio Inc Market Cap ($266.14 Million)
Market Cap & Net Worth: 2Seventy Bio Inc (TSVT)
2Seventy Bio Inc market cap. 2Seventy Bio Inc (NASDAQ:TSVT) has a market capitalization of $266.14 Million ($266.14 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15130 globally and #3594 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 2Seventy Bio Inc's stock price $5.00 by its total outstanding shares 53228300 (53.23 Million). Also see cash flow conversion of 2Seventy Bio Inc for how efficiently the company converts equity into cash flow.
2Seventy Bio Inc Market Cap History (2021–2025)
2Seventy Bio Inc market cap history from 2021 to 2025. Data shows change from $1.36 Billion to $266.14 Million (-24.82% CAGR). Check TSVT share price today for real-time trading data and today's change.
Index Memberships
2Seventy Bio Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.01% | #399 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #1468 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.01% | #206 of 263 |
Weight: 2Seventy Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
2Seventy Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 2Seventy Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of 2Seventy Bio Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.13x
2Seventy Bio Inc's market cap is 4.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.36 Billion | $54.52 Million | -$292.21 Million | 25.02x | N/A |
| 2022 | $498.75 Million | $91.50 Million | -$254.14 Million | 5.45x | N/A |
| 2023 | $227.28 Million | $100.39 Million | -$217.57 Million | 2.26x | N/A |
| 2024 | $156.49 Million | $37.86 Million | -$57.25 Million | 4.13x | N/A |
Competitor Companies of TSVT by Market Capitalization
Companies near 2Seventy Bio Inc in the global market cap rankings as of November 4, 2026. Also see total assets of 2Seventy Bio Inc for a full breakdown of the balance sheet.
Key companies related to 2Seventy Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of 2Seventy Bio Inc (2021–2025)
Market capitalization of 2Seventy Bio Inc from 2021 to today. Between 2021 and today, 2Seventy Bio Inc's market cap moved from $1.36 Billion to $ 266.14 Million, with a yearly change of -24.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $266.14 Million | +70.07% |
| 2024 | $156.49 Million | -31.15% |
| 2023 | $227.28 Million | -54.43% |
| 2022 | $498.75 Million | -63.44% |
| 2021 | $1.36 Billion | -- |
End of Day Market Cap According to Different Sources
On May 21st, 2026 the market cap of 2Seventy Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $266.14 Million USD |
| MoneyControl | $266.14 Million USD |
| MarketWatch | $266.14 Million USD |
| marketcap.company | $266.14 Million USD |
| Reuters | $266.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 2Seventy Bio Inc
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more